アブストラクト
| Title | 泌尿器がん |
|---|---|
| Subtitle | 特集2 免疫チェックポイント阻害薬の使い方 & irAE対策 臓器別にみるICIの使い方 |
| Authors | 泉浩二 |
| Authors (kana) | |
| Organization | 金沢大学泌尿器集学的治療学 |
| Journal | 月刊薬事 |
| Volume | 65 |
| Number | 6 |
| Page | 1117-1122 |
| Year/Month | 2023 / 5 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Key Point] ●再発リスクが高い腎細胞がんに対するペムブロリズマブ術後補助療法が承認されたが, 全生存の評価が不十分であり, 長期フォローの結果が待たれる. ●根治切除不能または転移性の腎細胞がんに対するファーストラインICI併用療法には5つの治療法があるが, その優劣はつけがたく, 症例に応じて適切に使い分ける必要がある. ●尿路上皮がんのニボルマブ術後補助療法は, 腎盂・尿管がんでは膀胱がんと比べ有効性が低い可能性があり, 適応には注意を要する. ●局所進行・転移性尿路上皮がんに対するファーストラインではICIの適応はないが, セカンドラインとファーストライン化学療法後の維持療法での適応があり, それぞれ対応する従来の化学療法よりも有害事象の軽減など, アドバンテージがあると考えられる. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Choueiri TK, et al ; KEYNOTE-564 Investigators : Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med, 385 : 683-694, 2021
- 2) Powles T, et al ; KEYNOTE-564 Investigators : Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma(KEYNOTE-564) : 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 20 : 1133-1144, 2022
- 3) Bedke J, et al : The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma. Eur Urol, 83 : 10-14, 2023
- 4) Motzer RJ, et al ; CheckMate 025 Investigators : Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med, 373 : 1803-1813, 2015
- 5) Heng DY, et al : Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents : results from a large, multicenter study. J Clin Oncol, 27 : 5794-5799, 2009
残りの22件を表示する
- 6) Flanigan RC, et al : Cytoreductive nephrectomy in patients with metastatic renal cancer : a combined analysis. J Urol, 171 : 1071-1076, 2004
- 7) Motzer RJ, et al ; CheckMate 214 Investigators : Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med, 378 : 1277-1290, 2018
- 8) Motzer RJ, et al : Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer, 128 : 2085-2097, 2022
- 9) Motzer RJ, et al : Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med, 380 : 1103-1115, 2019
- 10) Tomita Y, et al : Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma : long-term follow-up results from JAVELIN Renal 101. ESMO Open, 7 : 100564, 2022
- 11) Rini BI, et al ; KEYNOTE-426 Investigators : Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med, 380 : 1116-1127, 2019
- 12) Choueiri TK, et al ; CheckMate 9ER Investigators : Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med, 384 : 829-841, 2021
- 13) Choueiri TK, et al ; CheckMate 9ER Investigators : Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med, 384 : 829-841, 2021
- 14) Bersanelli M, et al : A metanalysis on cabozantinib and bone metastases : true story or commercial gimmick? Anticancer Drugs, 31 : 211-215, 2020
- 15) Motzer R, et al ; CLEAR Trial Investigators : Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med, 384 : 1289-1300, 2021
- 16) Lombardi P, et al : New first-line immunotherapy-based combinations for metastatic renal cell carcinoma : A system-atic review and network meta-analysis. Cancer Treat Rev, 106 : 102377, 2022
- 17) Bosma NA, et al : Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma : A Systematic Review and Network Meta-analysis. Eur Urol Open Sci, 37 : 14-26, 2022
- 18) Birtle A, et al : Adjuvant chemotherapy in upper tract urothelial carcinoma(the POUT trial) : a phase 3, open-label, randomised controlled trial. Lancet, 395 : 1268-1277, 2020
- 19) Bajorin DF, et al : Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med, 384 : 2102-2114, 2021
- 20) Bellmunt J, et al : The Efficacy of Second-line Chemotherapy for Advanced or Metastatic Urothelial Cancer. Anticancer Res, 40 : 1141-1146, 2020
- 21) Naito R, et al : The Efficacy of Second-line Chemotherapy for Advanced or Metastatic Urothelial Cancer. Anticancer Res, 40 : 1141-1146, 2020
- 22) Kadono Y, et al : Favorable Response of Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma with Only Small Lesions to not be Considered Measurable by RECIST. Urol J, 19 : 202-208, 2021
- 23) Powles T, et al : Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med, 383 : 1218-1230, 2020
- 24) Kawaguchi S, et al : Clinical Outcomes of Three or More Courses of First-line Chemotherapy for Metastatic Urothelial Carcinoma. Cancer Diagn Progn, 1 : 459-464, 2021
- 25) Galsky MD, et al ; IMvigor130 Study Group ; Atezolizumab with or without chemotherapy in metastatic urothelial cancer(IMvigor130) : a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, 395 : 1547-1557, 2020
- 26) Powles T, et al ; DANUBE study investigators : Durvalumab alone and durvalumab plus tremelimumab versus chemo-therapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma(DANUBE) : a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol, 21 : 1574-1588, 2020
- 27) Powles T, et al ; KEYNOTE-361 Investigators : Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma(KEYNOTE-361) : a randomised, open-label, phase 3 trial. Lancet Oncol, 22 : 931-945, 2021
